NOTICE OF A GENERAL MEETING OF IBA SA

Louvain-la-Neuve, Belgium, 21 November 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2024.

Fourth agreement secured by IBA Industrial Solutions in past six weeks

A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer

Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is focussed on the production of actinium-225, a novel radioisotope used in a new class of targeted treatments for cancer.

GROUP REVENUES UP 21.9%

Agreement further strengthens the long-term relationship between IBA and the University of Pennsylvania

HY24 results webcast to take place on
Thursday, 29 August 2024 at 3pm CEST

Louvain-la-Neuve, Belgium, 23 May 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter ending 31 March 2024.

Louvain-La-Neuve, Belgium, 2 May 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy Center, a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International, for the installation of a Proteus^®ONE¹ compact proton therapy system. The contract includes a multi-year operation and maintenance agreement, and it is expected that the center will start treating patients in the spring of 2026. The first downpayment has been received.